Currently Alzheimer’s disease and schizophrenia are both well-established neuropsychiatric diseases. Nonetheless, the treatment
of these disorders is not unanimous and fully effective. As a consequence, several approaches have been studied to improve patient’s
conditions. In this context, the development of new drug nanodelivery systems to increase drug bioavailability and reduce adverse
effects has been claimed as a good option. Among these systems we focus on the ones that seem to be most promising, such as lipidbased
systems (e.g. liposomes, nanoemulsions and lipid nanoparticles), drug nanocrystals, polymeric nanoparticles and micelles. Moreover,
the application of these systems by means of alternative administration routes is also discussed.
Regardless of the satisfactory results and the associated progresses that have been done in the last years, more studies are required to
quickly licence the application of drug nanodelivery systems in human medicines.